Surgical and medical perspective on healthspan, GLP-1 therapy, body composition, and what actually determines whether metabolic health lasts.
Roughly a quarter to 40% of what's lost on a GLP-1, without structured support, is muscle — not fat. Here's why that gap matters more than the number on the scale.
In follow-up visits, the number on the scale is one of the last things I ask about. Here's what I track instead, and why I send patients for DEXA scans between visits.
The most disciplined patients I've treated often struggled the most. Twenty-five years of surgery convinced me willpower was never the real variable.
What's a normal adjustment period, what's a sign to call your provider, and the practical habits that make the early weeks of a GLP-1 more tolerable.
More dose is not the same as more benefit. Why some patients do better finding their effective dose well within the standard range, rather than escalating to the top.
What's actually behind the interest in very low-dose GLP-1 use, why the term “microdosing” undersells the seriousness of it, and where the evidence really stands.
Weight loss was never the real goal. Why healthspan is the actual target, where GLP-1 therapy fits, and how peptide therapy plays a supporting role in comprehensive care.
The baseline concept behind everything else on this site: what metabolic health actually means, and why weight was never supposed to be the target itself.